Boston Scientific to Acquire Penumbra in Multi-Billion Dollar Cash and Stock Deal

summarizeSummary

Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. in a transaction valued at approximately $14.39 billion, combining cash and stock consideration, significantly expanding Boston Scientific's portfolio.

check_boxKey Events

• Definitive Merger Agreement Signed

  Boston Scientific Corporation entered into an Agreement and Plan of Merger to acquire Penumbra, Inc. through its wholly-owned subsidiary, Pinehurst Merger Sub, Inc.

• Significant Transaction Value

  The acquisition is estimated to be valued at approximately $14.39 billion, based on Penumbra's 39,229,670 outstanding shares and a blended consideration of cash and Boston Scientific stock.

• Mixed Cash and Stock Consideration

  Penumbra shareholders will receive $374.00 in cash for 73.26% of their shares and 3.8721 Boston Scientific shares for 26.74% of their shares, subject to proration.

• Substantial Regulatory Termination Fees

  Boston Scientific is obligated to pay a $900 million termination fee if the merger fails due to regulatory approval issues, while Penumbra would pay $525 million for a superior proposal.

auto_awesomeAnalysis

This 8-K filing announces a highly significant acquisition for Boston Scientific, representing a substantial portion of its current market capitalization. The definitive agreement to acquire Penumbra, Inc. is estimated to be valued at approximately $14.39 billion, based on a blended consideration of cash and Boston Scientific stock. Penumbra shareholders will receive $374.00 in cash for 73.26% of their shares and 3.8721 Boston Scientific shares for the remaining 26.74% of shares, subject to proration. The transaction is contingent on Penumbra stockholder approval and various regulatory clearances, including HSR Act requirements. The agreement includes substantial termination fees, with Boston Scientific obligated to pay $900 million if the merger fails due to regulatory approval issues, highlighting potential antitrust scrutiny. This acquisition, occurring while Boston Scientific's stock is trading near its 52-week low, marks a major strategic move to expand its market presence and product offerings. Investors should monitor the progress of regulatory approvals and the integration plan for the combined entity.